Myriad Genetics Overview
Myriad Genetics Target Price
Analysts' 12-month price predictions for MYGN.
Share Price
$5.53
Average Target Price
$11.00
98.9% upside
98.9% upside5 analysts in the last 4 months
High: $18 | Low: $6
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-05-07 | Craig-HallumBill Bonello | $18 | 225.5% upside |  |
| 2025-05-07 | UBSLu Li | $7 | 26.6% upside | |
| 2025-05-07 | Wells FargoBrandon Couillard | $6 | 8.5% upside | |
| 2025-03-12 | Piper Sandler | $12.5 | 126% upside | |
| 2025-03-04 | Piper Sandler | $11.5 | 108% upside | |
| 2024-12-09 | Leerink PartnersPuneet Souda | $21 | 279.7% upside | |
| 2024-10-14 | ScotiabankSung Ji Nam | $34 | 514.8% upside | |
| 2024-09-19 | Morgan StanleyTejas Savant | $32 | 478.7% upside | |
| 2024-08-27 | Wells FargoBrandon Couillard | $35 | 532.9% upside | |
| 2024-08-07 | GuggenheimSubbu Nambi | $29 | 424.4% upside | |
| 2024-06-26 | ScotiabankSung Ji Nam | $29 | 424.4% upside | |
| 2024-05-13 | Piper SandlerJon Peterson | $28 | 406.3% upside | |
| 2023-12-21 | Piper SandlerDavid Westenberg | $23 | 315.9% upside | |
| 2022-10-05 | StephensMason Carrico | $22 | 297.8% upside | |
| 2022-04-19 | Goldman Sachs | $23 | 315.9% upside | |